Microbiome in Lung Cancer and Other Malignancies

Cancer Clinical Trial

Official title:

The Role of Microbiome in Lung Cancer and Other Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03688347
• Other study ID #: 201712819
• Status: Completed
• Start date: August 30, 2018
• Est. completion date: May 9, 2022

Study information

• Verified date: May 2022
• Source: University of Iowa
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To characterize the fecal, skin, nasal and oral microbiome and metabolome in patients with lung cancer and other malignancies, and correlate to treatment response and toxicities of various therapies including immunotherapy, chemotherapy and targeted therapy, etc.

Description:

Patients will be asked to provide nasal, oral and skin swabs, as well as stool samples during their regular clinic visits, at the baseline before desired therapy is given, and at the time when treatment is changed due to either disease progression or unbearable toxicities leading to treatment stop/change. If treatment stop/held is due to toxicities, a 3rd set of samples will be collected when toxicities reduce to less than grade 1. The samples will be subjected to DNA extraction followed by 16S rRNA and/or shotgun sequencing metagenomic analysis. The data will be correlated to clinical response from treatments, toxicities, clinical data (use of antibiotics, PPIs, lab parameters, etc.) and tissue genetic/immunological characteristics (mutations, PDL1 expression, etc.) for review of response. This is not data to be used for treatment of these subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: May 9, 2022
• Est. primary completion date: September 23, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

Patients diagnosed with lung cancer and other malignancies who are candidates for systemic therapies such as immunotherapy and chemotherapy

Eligibility criteria for studying microbiome in patients receiving immunotherapy:

• Patients with advanced/recurrent lung cancer (including both NSCLC and SCLC) and other solid tumors of our study interest (e.g. GU cancer and melanoma, etc.) that initiate a new line of immunotherapy (can be 1st or later line), either alone or in combination with chemotherapy, targeted therapy or other immunotherapy.

• Patients can be in other clinical trials as long as they meet criteria 1.

• Prior treatment with immunotherapy is acceptable as long as criteria 1 is met. For example, a new line therapy with pembrolizumab plus pemetrexed after failing pembrolizumab is considered eligible.

• Patients who are to start immunotherapy maintenance after chemoradiation therapy are eligible (e.g. NSCLC patients who will be on durvalumab maintenance)

• Patients who are to start immunotherapy after local therapies (e.g. radiation, ablation, etc.) are eligible.

• Immunotherapy must have component of anti-PD-1/PD-L1 agents (e.g. nivolumab, pembrolizumab, atezolizumab, durvalumab and avelumab, etc.) or anti-CTLA4 (e.g. ipilimumab)

Exclusion Criteria:

• Patients < 18 years of age

• Patients that are pregnant

• Patients taking more than 2 alcoholic drinks per day and those using non-medical drugs such as marijuana, cocaine, heroine, etc.

Related Conditions & MeSH terms

• Cancer
• Lung Cancer
• Lung Neoplasms
• Malignancy
• Neoplasms

Intervention

Procedure:
• Nasal Swab
The swab is removed from packaging, moistened with sterile water if needed to prevent any discomfort to the participant. The swab is gently inserted less than one inch into the anterior nare (nostril) until resistance is met at turbinate. Then it is rotated several times against nasal wall and repeated in other nostril using the same swab.
• Oral Swab
The swab is removed from packaging, moistened with sterile water if needed to prevent any discomfort to the participant. The swab is gently rubbed along the inside of the participant's cheek for 5-10 seconds.

Other:
• Stool Collection
A stool collection kit will be sent home with each participant. It will include instructions on how to collect the stool specimen and how to return the kit.

Genetic:
• Microbiome analysis
Study of microbial communities found in and on the human body.
• DNA Banking
Secure, long term storage of an individual's genetic material.

Procedure:
• Skin Swab
Gentle rubbing of the swab will be applied to the skin on the dorsal part of the hand.

Locations

Country	Name	City	State
United States	University of Iowa Hospitals and Clinics	Iowa City	Iowa

Sponsors (3)

Lead Sponsor	Collaborator
Taher Abu Hejleh	Holden Comprehensive Cancer Center, Iowa Institute of Human Genetics

Country where clinical trial is conducted

United States, 

References & Publications (2)

Strouse C, Mangalam A, Zhang J. Bugs in the system: bringing the human microbiome to bear in cancer immunotherapy. Gut Microbes. 2019;10(2):109-112. doi: 10.1080/19490976.2018.1511665. Epub 2018 Sep 5. — View Citation

Swami U, Zakharia Y, Zhang J. Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces Together. J Immunother. 2018 Oct;41(8):359-360. doi: 10.1097/CJI.0000000000000232. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identify and compare bacteria within given samples through standard protocol and 16S rRNA amplicon	Bacterial DNA will be isolated from stool/swab samples using standard protocol. Fecal micobiota will be examined based on an 16S rRNA amplicon.	Time of study enrollment up to one year
Secondary	Correlate data from samples with patient clinical information	Correlate data from samples with patient clinical information regarding overall response rates.	Time of study enrollment up to one year
Secondary	Number of treatment related adverse events (AE) as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0	Record from each clinical visit the AEs from immunotherapy or its combination with chemotherapy.	Time of study enrollment up to one year